Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2000 Sep;55(9):762–767. doi: 10.1136/thorax.55.9.762

Asthma exacerbations during long term β agonist use: influence of β2 adrenoceptor polymorphism

D Taylor 1, J Drazen 1, G Herbison 1, C Yandava 1, R Hancox 1, G Town 1
PMCID: PMC1745862  PMID: 10950895

Abstract

BACKGROUND—Polymorphisms of the β2 adrenoceptor influence receptor function in vitro and asthma phenotypes in vivo. However, their importance in determining responses to inhaled β agonist treatment has not been clearly defined.
METHODS—In a retrospective analysis of previously published data we have examined relationships between polymorphisms at codons 16and 27 of the β2 adrenoceptor and clinical outcomes in a randomised, placebo controlled, crossover trial of regularly scheduled salbutamol and salmeterol in 115 patients with mild to moderate asthma. Genotyping was obtained for positions 16 and 27 in 108 and 107 patients, respectively. For position 16, 17 patients (16%) were homozygous Arg-Arg, 40 (37%) were heterozygous Arg-Gly, and 51 (47%) were homozygous Gly-Gly.
RESULTS—Within the homozygous Arg-16 group major exacerbations were more frequent during salbutamol treatment than with placebo (1.91(95% CI 1.07 to 3.12) per year versus 0.81 (95% CI 0.28 to 1.66) per year; p = 0.005). No significant treatment related differences occurred for heterozygous Arg-Gly patients (salbutamol 0.11 (95% CI 0.01 to 0.40), placebo 0.54 (95% CI 0.26 to 1.00) exacerbations per year) or homozygous Gly-16 patients (salbutamol 0.38 (95% CI 0.17 to 0.73), placebo 0.30 (95% CI 0.12 to 0.61) exacerbations per year). No adverse changes occurred for any position 16 subgroup with salmeterol. There was no significant relationship between position 27 genotypes and treatment related outcomes.
CONCLUSION—Homozygous Arg-16 patients are susceptible to clinically important increases in asthma exacerbations during chronic dosing with the short acting β2 agonist salbutamol.



Full Text

The Full Text of this article is available as a PDF (166.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cockcroft D. W., Swystun V. A. Functional antagonism: tolerance produced by inhaled beta 2 agonists. Thorax. 1996 Oct;51(10):1051–1056. doi: 10.1136/thx.51.10.1051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Dewar J. C., Wheatley A. P., Venn A., Morrison J. F., Britton J., Hall I. P. Beta2-adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population. Clin Exp Allergy. 1998 Apr;28(4):442–448. doi: 10.1046/j.1365-2222.1998.00245.x. [DOI] [PubMed] [Google Scholar]
  3. Eisenstadt W. S., Nicholas S. S. The adverse effect of adrenergic aerosols in bronchial asthma. Ann Allergy. 1969 Jun;27(6):283–288. [PubMed] [Google Scholar]
  4. Green S. A., Turki J., Bejarano P., Hall I. P., Liggett S. B. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol. 1995 Jul;13(1):25–33. doi: 10.1165/ajrcmb.13.1.7598936. [DOI] [PubMed] [Google Scholar]
  5. Green S. A., Turki J., Innis M., Liggett S. B. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 1994 Aug 16;33(32):9414–9419. doi: 10.1021/bi00198a006. [DOI] [PubMed] [Google Scholar]
  6. Hall I. P. Beta 2 adrenoceptor polymorphisms: are they clinically important? Thorax. 1996 Apr;51(4):351–353. doi: 10.1136/thx.51.4.351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hall I. P., Wheatley A., Wilding P., Liggett S. B. Association of Glu 27 beta 2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet. 1995 May 13;345(8959):1213–1214. doi: 10.1016/s0140-6736(95)91994-5. [DOI] [PubMed] [Google Scholar]
  8. Hancox R. J., Sears M. R., Taylor D. R. Polymorphism of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma. Eur Respir J. 1998 Mar;11(3):589–593. [PubMed] [Google Scholar]
  9. Liggett S. B. Polymorphisms of the beta2-adrenergic receptor and asthma. Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 2):S156–S162. doi: 10.1164/ajrccm.156.4.12tac-15. [DOI] [PubMed] [Google Scholar]
  10. Lima J. J., Thomason D. B., Mohamed M. H., Eberle L. V., Self T. H., Johnson J. A. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther. 1999 May;65(5):519–525. doi: 10.1016/S0009-9236(99)70071-8. [DOI] [PubMed] [Google Scholar]
  11. Martinez F. D., Graves P. E., Baldini M., Solomon S., Erickson R. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest. 1997 Dec 15;100(12):3184–3188. doi: 10.1172/JCI119874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. McGraw D. W., Forbes S. L., Kramer L. A., Liggett S. B. Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J Clin Invest. 1998 Dec 1;102(11):1927–1932. doi: 10.1172/JCI4862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Pauwels R. A., Löfdahl C. G., Postma D. S., Tattersfield A. E., O'Byrne P., Barnes P. J., Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997 Nov 13;337(20):1405–1411. doi: 10.1056/NEJM199711133372001. [DOI] [PubMed] [Google Scholar]
  14. Rand C. S., Nides M., Cowles M. K., Wise R. A., Connett J. Long-term metered-dose inhaler adherence in a clinical trial. The Lung Health Study Research Group. Am J Respir Crit Care Med. 1995 Aug;152(2):580–588. doi: 10.1164/ajrccm.152.2.7633711. [DOI] [PubMed] [Google Scholar]
  15. Reisman R. E. Asthma induced by adrenergic aerosols. J Allergy. 1970 Sep;46(3):162–177. doi: 10.1016/0021-8707(70)90095-x. [DOI] [PubMed] [Google Scholar]
  16. Tan S., Hall I. P., Dewar J., Dow E., Lipworth B. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet. 1997 Oct 4;350(9083):995–999. doi: 10.1016/S0140-6736(97)03211-X. [DOI] [PubMed] [Google Scholar]
  17. Taylor D. R., Town G. I., Herbison G. P., Boothman-Burrell D., Flannery E. M., Hancox B., Harré E., Laubscher K., Linscott V., Ramsay C. M. Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol. Thorax. 1998 Sep;53(9):744–752. doi: 10.1136/thx.53.9.744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Turki J., Pak J., Green S. A., Martin R. J., Liggett S. B. Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. J Clin Invest. 1995 Apr;95(4):1635–1641. doi: 10.1172/JCI117838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Weir T. D., Mallek N., Sandford A. J., Bai T. R., Awadh N., Fitzgerald J. M., Cockcroft D., James A., Liggett S. B., Paré P. D. beta2-Adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma. Am J Respir Crit Care Med. 1998 Sep;158(3):787–791. doi: 10.1164/ajrccm.158.3.9801035. [DOI] [PubMed] [Google Scholar]
  20. Yandava C. N., Zappulla D. C., Korf B. R., Neufeld E. J. ARMS test for diagnosis of factor VLeiden mutation, a common cause of inherited thrombotic tendency. J Clin Lab Anal. 1996;10(6):414–417. doi: 10.1002/(SICI)1098-2825(1996)10:6<414::AID-JCLA17>3.0.CO;2-#. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES